Search

everythinglearnresearchcommunity

for

Search:↓

The combination treatment showed a higher response rate but no significant survival benefits.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Topical tofacitinib shows promise as a future treatment for alopecia areata.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.

TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.

A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.

A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.

Lokivetmab reduced itching in a dog with skin lymphoma.

Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.

The combination therapy was effective and well-tolerated, especially in young patients.

Intralesional methotrexate effectively treats patchy alopecia areata by reducing inflammation.

Brodalumab is more effective than ustekinumab in treating psoriasis.

Axitinib treatment turned a man's grey hair back to black.

Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.

An AI device for skin cancer was successfully integrated into the NHS, improving diagnosis accuracy and service capacity.

IL-17 inhibitors for psoriasis may cause unexpected hair loss.

NLRP1 helps melanoma tumors grow by boosting inflammasome activation and reducing caspase-3 activity.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

JAK-inhibitors are effective for treating psoriasis and show promise for other skin diseases.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.

JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.